Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis
All‐cause mortality · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with low molecular weight heparin secondary prophylaxis (low certainty).
1 finding from 1 review
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes onlyRR 0.97 [0.83, 1.14]5 studies · 2854 participantsLow